Boletim informativo corporativo

GEA to highlight the benefits of partnership during vaccine plant production at ACHEMA Pulse

24 Mar 2021

GEA, one of the world's leading companies in mechanical and plant engineering, will participate in the upcoming virtual ACHEMA Pulse (15–16 June) and address some of the key issues facing today’s manufacturers of biopharmaceuticals.

GEA is committed to “Engineering for a better world,” designing and building modular plants and fully integrated systems that meet the extremely high demands of today’s biotechnology and pharmaceutical industries. (Courtesy: Damian Poffet)

GEA is committed to “Engineering for a better world,” designing and building modular plants and fully integrated systems that meet the extremely high demands of today’s biotechnology and pharmaceutical industries. (Courtesy: Damian Poffet)

Despite the incredible achievements that have been made in terms of developing and delivering a number of approved and administered Covid-19 vaccines in recent times, governments, politicians and the general public alike are still questioning why it takes 3-5 years to bring a commercial-scale biopharmaceutical manufacturing plant to full operational functionality.

Furthermore, they want to know what can be done about it. GEA Group’s Heinrich Meintrup, Head of Pharma & Healthcare, believes that the key to significantly shortening this timeframe is modularization, digitalization and collaboration. In his presentation, “How Can We Fast-Track Vaccine Plant Production and Ensure Safety of Outcome?” he will explain how, based on a foundation of trust and existing know-how, working with a partnership approach can reduce the complexity, cost and risk of successful drug production.

By subscribing to a philosophy of standardization and modularization, a digitally enhanced project delivery process and keeping the number of interfaces to a minimum, significant gains can be made.

“We have to make the best use of existing intelligent solutions,” advises Meintrup, “adhere to current standards and regulations, and focus on mutually agreed targets and incentives. Disruptions and delays can cost millions of dollars; but, by taking a smarter and leaner approach, GEA believes that the design, construction and qualification of pharmaceutical manufacturing plant and facilities can be accelerated, simplified and delivered with predictable outcomes in a shorter timeframe.”

Contact

Dr. Michael Golek

Phone: 49 211 9136 1505

Media Relations

GEA Group Aktiengesellschaft

Peter-Müller-Str. 12


40468

Düsseldorf


Germany

+49 211 9136-0

About GEA

A GEA é uma das maiores fornecedoras para a indústria de processamento de alimentos e para uma ampla variedade de outras indústrias que geraram receitas consolidadas de aproximadamente EUR 4,9 bilhões em 2019.

O grupo internacional de tecnologia é especializado em maquinaria e plantas, além de tecnologia e componentes para processamentos. A GEA fornece soluções de energia sustentável para processos de produção sofisticados em diversos mercados de usuários finais e oferece um portfólio abrangente de serviços. O grupo gera cerca de 70% da sua receita no setor de alimentos e bebidas, que desfruta de um crescimento sustentável a longo prazo. Desde 31 de dezembro de 2018, a empresa empregou mais de 18.500 pessoas em todo o mundo. A GEA é líder de mercado e tecnologia em suas áreas de negócios. A empresa está listada na bolsa alemã MDAX (G1A, WKN 660 200), no Índice STOXX® Europe 600 e nos Índices selecionados de Sustentabilidade Global MSCI. Maiores informações disponíveis na Internet em gea.com. Se você não quiser mais receber informações da GEA, por favor envie um e-mail para pr@gea.com.
Receba notícias da GEA

Mantenha-se atualizado com as inovações e histórias da GEA, se registrando para receber notícias sobre a GEA.

Entre em contato

Estamos aqui para ajudar! Com apenas poucos detalhes poderemos responder à sua pergunta.